Document is current
Any future updates will be listed below
-
Authors
Giuffrida, Lauren
Sek, Kevin https://orcid.org/0000-0003-4634-7600
Henderson, Melissa A.
Lai, Junyun
Chen, Amanda X. Y.
Meyran, Deborah
Todd, Kirsten L.
Petley, Emma V.
Mardiana, Sherly https://orcid.org/0000-0002-4045-7836
Mølck, Christina
Stewart, Gregory D.
Solomon, Benjamin J.
Parish, Ian A. https://orcid.org/0000-0003-3528-478X
Neeson, Paul J. https://orcid.org/0000-0002-2729-5887
Harrison, Simon J. https://orcid.org/0000-0003-4555-6582
Kats, Lev M. https://orcid.org/0000-0001-8742-8138
House, Imran G. https://orcid.org/0000-0002-6245-5954
Darcy, Phillip K. https://orcid.org/0000-0002-5303-9561
Beavis, Paul A. https://orcid.org/0000-0002-2116-013X
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP1122444)
National Breast Cancer Foundation (ECF-17-005)
- License Information
-
More Information
Article History
Received: 9 August 2020
Accepted: 22 April 2021
First Online: 28 May 2021
Competing interests
: S.J.H. declares the following competing interests: Consultancy: Amgen, Celgene, Novartis, Janssen-Cilag, Haemalogix, GSK. Research funding: Celgene, Janssen-Cilag, and Novartis. L.M.K declares the following conflicts: consultancy and research funding from Agios and Celgene. P.K.D. declares the following conflicts: research funding from Myeloid Therapeutics, Prescient Therapeutics, and Juno Therapeutics. P.A.B. declares the following conflicts: research funding from AstraZeneca and Gilead Sciences. The remaining authors declare no competing interests.
